The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Impact of early NGS MRD negativity on outcomes in B-cell ALL: A retrospective analysis
|
Although MRD negativity is an important clinical endpoint in ALL, it is unclear whether NGS MRD negativity can improve the prognosis in patients with high-risk ALL. During the 66th ASH Annual Meeting and Exposition, Walid Macaron presented results from a retrospective analysis assessing the impact of NGS MRD negativity (1 x 10-6) on outcomes in patients with newly diagnosed B-cell ALL (N = 161).1 |
| Key learnings |
|
Compared with NGS MRD positivity, MRD negativity was associated with higher 2-year RFS at 1.5 months (94% vs 66%; p = 0.03), 3 months (82% vs 65%; p = 0.08), and 6 months (82% vs 62%; p = 0.01). |
| The 2-year RFS was higher in patients with Ph- B-cell ALL who were MRD negative at 1.5 months (100% vs 69%; p = 0.03), 3 months (83% vs 60%; p = 0.04), and 6 months (87% vs 50%; p < 0.001) compared with those who were MRD positive. |
| Among MRD-positive patients, 2-year RFS was higher at 1.5 months (80% vs 0%; p = 0.009) and 3 months (86% vs 21%; p = 0.02) in those who received allo-HSCT vs those who did not. |
| These findings show that early achievement of NGS MRD negativity is associated with favorable outcomes in patients with high-risk B-cell ALL, and that NGS-based MRD assessment should be incorporated into risk stratification and treatment protocols. |
Abbreviations: ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; ASH, American Society of Hematology; MRD, measurable residual disease; NGS, next-generation sequencing; Ph-, Philadelphia chromosome-negative; RFS, relapse-free survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
